Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.

Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A

Open source

DOI: 10.2174/138920101606150407114407
Published: 2015
Container: Current pharmaceutical biotechnology
Publisher: Not recorded
Open access: unknown

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2174/138920101606150407114407,
  title = {Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.},
  author = {Zalazar F and De Luca P and Gardner K and Figg WD and Meiss R and Spallanzani RG and Vallecorsa P and Elguero B and Cotignola J and Vazquez E and De Siervi A},
  year = {2015},
  journal = {Current pharmaceutical biotechnology},
  doi = {10.2174/138920101606150407114407},
  url = {https://doi.org/10.2174/138920101606150407114407}
}

RIS

TY  - JOUR
TI  - Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.
AU  - Zalazar F
AU  - De Luca P
AU  - Gardner K
AU  - Figg WD
AU  - Meiss R
AU  - Spallanzani RG
AU  - Vallecorsa P
AU  - Elguero B
AU  - Cotignola J
AU  - Vazquez E
AU  - De Siervi A
PY  - 2015
JO  - Current pharmaceutical biotechnology
DO  - 10.2174/138920101606150407114407
UR  - https://doi.org/10.2174/138920101606150407114407
ER  -

APA

F, Z., P, D. L., K, G., WD, F., R, M., RG, S., P, V., B, E., J, C., E, V., & A, D. S. (2015). Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.. Current pharmaceutical biotechnology. https://doi.org/10.2174/138920101606150407114407

Source records

pubmed · retrieved 2026-09-25T22:48:00.756Z